{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:14:46Z","timestamp":1793146486391,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30DK079337"],"award-info":[{"award-number":["P30DK079337"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK106102"],"award-info":[{"award-number":["R01DK106102"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL139836"],"award-info":[{"award-number":["R01HL139836"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1DK112042"],"award-info":[{"award-number":["RO1DK112042"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.amjcard.2019.10.027","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T19:01:57Z","timestamp":1573758117000},"page":"S28-S35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"S1","title":["Renal Effects of Sodium-Glucose Co-Transporter Inhibitors"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8853-0505","authenticated-orcid":false,"given":"Scott C.","family":"Thomson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Vallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2019.10.027_bb0005","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.2337\/db13-0604","article-title":"Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans","volume":"62","author":"Abdul-Ghani","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0010","first-page":"61","article-title":"On the action of phlorizin","volume":"10","author":"Stiles","year":"1903","journal-title":"Am J Phys"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0015","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0020","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1172\/JCI112981","article-title":"Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats","volume":"79","author":"Rossetti","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0025","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2337\/dc13-2762","article-title":"Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study","volume":"38","author":"Leiter","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0030","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","article-title":"Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"4","author":"Weber","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0035","doi-asserted-by":"crossref","first-page":"F173","DOI":"10.1152\/ajprenal.00462.2018","article-title":"SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1","volume":"316","author":"Novikov","year":"2019","journal-title":"Am J Physiol Renal Physiol."},{"key":"10.1016\/j.amjcard.2019.10.027_bb0040","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0045","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials","volume":"20","author":"Zhao","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0050","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/ki.2010.510","article-title":"Effect of kidney disease on glucose handling (including genetic defects)","volume":"79","author":"Calado","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0055","doi-asserted-by":"crossref","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","article-title":"Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia","volume":"306","author":"Rieg","year":"2014","journal-title":"Am J Physiol Renal Physiol."},{"key":"10.1016\/j.amjcard.2019.10.027_bb0060","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0065","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.2337\/dc13-0663","article-title":"Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes","volume":"36","author":"Ferrannini","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0070","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1152\/ajpregu.00357.2011","article-title":"Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat","volume":"302","author":"Thomson","year":"2012","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"key":"10.1016\/j.amjcard.2019.10.027_bb0075","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1172\/JCI100690","article-title":"The excretion of inulin, xylose and urea by normal and phlorizinized man","volume":"14","author":"Shannon","year":"1935","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0080","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0085","unstructured":"US Food and Drug Administration. Guidance for industry: diabetes mellitus\u2014evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071627.pdf. Accessed on March 26, 2019."},{"key":"10.1016\/j.amjcard.2019.10.027_bb0090","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12933-018-0667-2","article-title":"Report from the 3rd cardiovascular outcome trial (CVOT) summit of the diabetes & cardiovascular disease (D&CVD) EASD study group","volume":"17","author":"Schnell","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0095","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12933-017-0508-8","article-title":"Report from the 2nd cardiovascular outcome trial (CVOT) summit of the diabetes and cardiovascular disease (D&CVD) EASD study group","volume":"16","author":"Schnell","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0100","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12933-019-0822-4","article-title":"Report from the 4th cardiovascular outcome trial (CVOT) summit of the diabetes & cardiovascular disease (D&CVD) EASD study group","volume":"18","author":"Schnell","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0105","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11892-018-0991-7","article-title":"Renal effects of incretin-based diabetes therapies: pre-clinical predictions and clinical trial outcomes","volume":"18","author":"Thomson","year":"2018","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0110","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0115","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0120","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0125","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0130","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0135","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0140","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0145","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/ki.1997.111","article-title":"A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function","volume":"51","author":"Apperloo","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0150","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3109\/00365518609083660","article-title":"Early glomerular hyperfiltration in insulin-dependent diabetics and late nephropathy","volume":"46","author":"Mogensen","year":"1986","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0155","doi-asserted-by":"crossref","first-page":"F8","DOI":"10.1152\/ajprenal.00208.2003","article-title":"Kidney function in early diabetes: the tubular hypothesis of glomerular filtration","volume":"286","author":"Thomson","year":"2004","journal-title":"Am J Physiol Renal Physiol."},{"key":"10.1016\/j.amjcard.2019.10.027_bb0160","doi-asserted-by":"crossref","first-page":"R1009","DOI":"10.1152\/ajpregu.00809.2010","article-title":"The proximal tubule in the pathophysiology of the diabetic kidney","volume":"300","author":"Vallon","year":"2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0165","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1093\/ndt\/gfq008","article-title":"Glomerular hyperfiltration and increased proximal sodium reabsorption in subjects with type 2 diabetes or impaired fasting glucose in a population of the African region","volume":"25","author":"Pruijm","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0170","first-page":"F946","article-title":"Tubular sodium handling and tubuloglomerular feedback in experimental diabetes mellitus","volume":"260","author":"Pollock","year":"1991","journal-title":"Am J Phys"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0175","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1681\/ASN.V10122569","article-title":"Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption","volume":"10","author":"Vallon","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0180","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1681\/ASN.2013060588","article-title":"Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+\/H+ exchanger isoform 3 activity in the renal proximal tubule","volume":"25","author":"Pessoa","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0185","first-page":"A132","article-title":"SGLT2 inhibitor empagliflozin increases renal NHE3 phosphorylation in diabetic Akita mice: possible implications for the prevention of glomerular hyperfiltration","volume":"63","author":"Fu","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0190","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1096\/fasebj.2018.32.1_supplement.620.17","article-title":"Tubular NHE3 is a determinant of the acute natriuretic and chronic blood pressure lowering effect of the SGLT2 inhibitor empagliflozin","volume":"32","author":"Huang","year":"2018","journal-title":"FASEB J"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0195","doi-asserted-by":"crossref","first-page":"F419","DOI":"10.1152\/ajprenal.00497.2018","article-title":"Effect of renal tubule-specific knockdown of the Na+\/H+ exchanger NHE3 in Akita diabetic mice","volume":"317","author":"Onishi","year":"2019","journal-title":"Am J Physiol Renal Physiol."},{"key":"10.1016\/j.amjcard.2019.10.027_bb0200","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.2215\/CJN.10391012","article-title":"Proximal tubule function and response to acidosis","volume":"9","author":"Curthoys","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0205","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/cvr\/cvz004","article-title":"Delayed ischemic contracture onset by empagliflozin associates with NHE-1 inhibition and is dependent on insulin in isolated mouse hearts","volume":"115","author":"Uthman","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0210","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action","volume":"2","author":"Packer","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0215","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0220","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0225","doi-asserted-by":"crossref","first-page":"F732","DOI":"10.1152\/ajprenal.00340.2003","article-title":"Early diabetes as a model for testing the regulation of juxtaglomerular NOS I","volume":"287","author":"Thomson","year":"2004","journal-title":"Am J Physiol Renal Physiol."},{"key":"10.1016\/j.amjcard.2019.10.027_bb0230","doi-asserted-by":"crossref","first-page":"F573","DOI":"10.1152\/ajprenal.2000.279.3.F573","article-title":"Role of neuronalnitric oxide synthase (NOS1) in the pathogenesis of renal hemodynamic changes in diabetes","volume":"279","author":"Komers","year":"2000","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0235","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1681\/ASN.2018080844","article-title":"Macula densa SGLT1-NOS1-tubuloglomerular feedback pathway, a new mechanism for glomerular hyperfiltration during hyperglycemia","volume":"30","author":"Zhang","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjcard.2019.10.027_bb0240","doi-asserted-by":"crossref","first-page":"F207","DOI":"10.1152\/ajprenal.00120.2019","article-title":"Knockout of Na-glucose-cotransporter SGLT1 mitigates diabetes-induced upregulation of nitric oxide synthase-1 in macula densa and glomerular hyperfiltration","volume":"317","author":"Song","year":"2019","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919311774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919311774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:05:05Z","timestamp":1762077905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914919311774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":48,"alternative-id":["S0002914919311774"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.10.027","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renal Effects of Sodium-Glucose Co-Transporter Inhibitors","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.10.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}